Citations

Clear

9383 citation(s) found for "Thomas, PS".

B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders
Feldman, Andrew L. , Wada, David A., Yang, Zhi‐Zhang, Comfere, Nneka I. , Dong, Haidong , Kwon, Eugene D., Novak, Anne J. , Pittelkow, Mark R. , Ansell, Stephen M. , Wilcox, Ryan A. , Markovic, Svetomir N. , Witzig, Thomas E. , Feldman, Andrew L , Dong, Haidong

Mayo Clinic

Blood | July 14, 2009 | Volume: 114 | Issue: 10 | Pages: 2149-2158

10.1182/blood-2009-04-216671 | PMID 19597183 Get It

AbstractStromal elements present within the tumor microenvironment may suppress host immunity and promote the growth of malignant lymphocytes in B cell–derived non-Hodgkin lymphoma (NHL). In contrast, little is known about the microenvironment's role in T cell–derived NHL. B7-H1 (PD-L1, CD274), a member of the B7 family of costimulatory/coinhibitory ligands expressed by both malignant cells and stromal cells within the tumor microenvironment, has emerged as an important immune modulator capable of suppressing host immunity. Therefore, B7-H1 expression and function were analyzed in cutaneous and peripheral T-cell NHL. B7-H1 was expressed by tumor cells, monocytes, and monocyte-derived cells within the tumor microenvironment in T-cell NHL and was found to inhibit T-cell proliferation and promote the induction of FoxP3+ regulatory T cells. Collectively, the data presented provide the first evidence implicating B7-H1 in the suppression of host immunity in T-cell lymphoproliferative disorders and suggest that the targeting of B7-H1 may represent a novel therapeutic approach.
Catecholamine Interference in Enzymatic Creatinine Assays
Saenger, Amy K., Lockwood, Christina M. , Snozek, Christine L.H. , Milz, Thomas C., Karon, Brad S. , Scott, Mitchell G., Jaffe, Allan S. , Jaffe, Allan S.

Mayo Clinic

Clinical Chemistry | July 9, 2009 | Volume: 55 | Issue: 9 | Pages: 1732-1736

10.1373/clinchem.2009.127373 | PMID 19589845 Get It

Abstract Background: Enzymatic creatinine assays are routinely used in clinical laboratories to provide more accurate estimated glomerular filtration rates and to avoid a perceived lack of analytical specificity associated with picrate (Jaffe) methods. Negative interferences with the enzymatic creatinine assay, which we noted in several patients on dopamine or dobutamine, prompted our further investigation into interference of catecholamines with enzymatic methods. Methods: Spiked solutions of dopamine, dobutamine, epinephrine, and norepinephrine were added to pooled sera at catecholamine concentrations consistent with clinically relevant dosing. Creatinine was measured enzymatically on the Roche P-Modular, Ortho Clinical Diagnostics Vitros 350, and Abbott i-STAT. Jaffe methods were performed on the Roche P-Modular and Siemens Dimension RxL. In 10 patients receiving dopamine and/or dobutamine via a venous or arterial line we evaluated and compared the extent of in vivo creatinine interference in paired serum samples obtained by venipuncture and from indwelling catheters. Results: All catecholamines caused significant negative interference with the Roche enzymatic creatinine assay, most pronounced for dopamine and dobutamine. The Vitros enzymatic assay demonstrated slight negative interferences, and i-STAT enzymatic and Jaffe methods were unaffected by the presence of catecholamines. Significant (P < 0.001) differences in creatinine concentrations by Roche enzymatic vs Jaffe methods were observed in venipuncture specimens compared with arterial or venous catheter specimens, suggesting dopamine and dobutamine reversibly adhere to the catheter lumen. Conclusions: Negative interferences were pronounced for Roche enzymatic results in blood samples obtained from indwelling catheters, a phenomenon not observed in peripheral draws. Physicians and laboratorians should be alert to the possibility of a falsely low creatinine result and reevaluate questionable samples using a method unaffected by catecholamines.
Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
Poplin, Elizabeth, Rothenberg, Mace L., Höchster, Howard S. , Mitchell, Edith P. , O’Dwyer, Peter J. , Haller, Daniel G. , Catalano, Paul J. , Cella, David , Benson, Al B. , Feng, Yang , Berlin, Jordan D. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | July 7, 2009 | Volume: 27 | Issue: 23 | Pages: 3778-3785

10.1200/jco.2008.20.9007 | PMID 19581537 Get It

PurposeSingle-agent gemcitabine (GEM) is standard treatment of metastatic pancreatic cancer. Fixed-dose rate (FDR) GEM and GEM plus oxaliplatin have shown promise in early clinical trials. E6201 was designed to compare overall survival (OS) of standard weekly GEM 1,000 mg/m2/30 minutes versus GEM FDR 1,500 mg/m2/150 minutes or GEM 1,000 mg/m2/100 minutes/day 1 plus oxaliplatin 100 mg/m2/day 2 every 14 days (GEMOX).MethodsThis trial included patients with metastatic or locally advanced pancreatic cancer, normal organ function, and performance status of 0 to 2. The study was designed to detect a 33% difference in median survival (hazard ratio [HR] ≤ 0.75 for either of the experimental arms) with 81% power while maintaining a significance level of 2.5% in a two-sided test for each of the two primary comparisons.ResultsEight hundred thirty-two patients were enrolled. The median survival and 1-year survival were 4.9 months (95% CI, 4.5 to 5.6) and 16% for GEM, 6.2 months (95% CI, 5.4 to 6.9), and 21% for GEM FDR (HR, 0.83; stratified log-rank P = .04), and 5.7 months (95% CI, 4.9 to 6.5) and 21% for GEMOX (HR, 0.88; stratified log-rank P = .22). Neither of these differences met the prespecified criteria for significance. Survival was 9.2 months for patients with locally advanced disease, and 5.4 months for those with metastatic disease. Grade 3/4 neutropenia and thrombocytopenia were greatest with GEM FDR. GEMOX caused higher rates of nausea, vomiting, and neuropathy.ConclusionNeither GEM FDR nor GEMOX resulted in substantially improved survival or symptom benefit over standard GEM in patients with advanced pancreatic cancer.
The Effect of Vitamin D2 and Vitamin D3 on Intestinal Calcium Absorption in Nigerian Children with Rickets
Thacher, Tom D. , Obadofin, Michael O, Abrams, Steven A. , O'Brien, Kimberly O , Thacher, Thomas D

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 1, 2009 | Volume: 94 | Issue: 9 | Pages: 3314-3321

10.1210/jc.2009-0018 | PMID 19567516 Get It

Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Greenberg, Peter L. , Sun, Zhuoxin , Miller, Kenneth B., Bennett, John M. , Tallman, Martin S. , Dewald, Gordon W., Paietta, Elisabeth , Jagt, Richard van der , Houston, Jessie G., Thomas, Mary L., Cella, David , Rowe, Jacob M.

Mayo Clinic

Blood | June 29, 2009 | Volume: 114 | Issue: 12 | Pages: 2393-2400

10.1182/blood-2009-03-211797 | PMID 19564636 Get It

Abstract This phase 3 prospective randomized trial evaluated the efficacy and long-term safety of erythropoietin (EPO) with or without granulocyte colony-stimulating factor plus supportive care (SC; n = 53) versus SC alone (n = 57) for the treatment of anemic patients with lower-risk myelodysplastic syndromes. The response rates in the EPO versus SC alone arms were 36% versus 9.6%, respectively, at the initial treatment step, 47% in the EPO arm, including subsequent steps. Responding patients had significantly lower serum EPO levels (45% vs 5% responses for levels < 200 mU/mL vs ≥ 200 mU/mL) and improvement in multiple quality-of-life domains. With prolonged follow-up (median, 5.8 years), no differences were found in overall survival of patients in the EPO versus SC arms (median, 3.1 vs 2.6 years) or in the incidence of transformation to acute myeloid leukemia (7.5% and 10.5% patients, respectively). Increased survival was demonstrated for erythroid responders versus nonresponders (median, 5.5 vs 2.3 years). Flow cytometric analysis showed that the percentage of P-glycoprotein+ CD34+ marrow blasts was positively correlated with longer overall survival. In comparison with SC alone, patients receiving EPO with or without granulocyte colony-stimulating factor plus SC had improved erythroid responses, similar survival, and incidence of acute myeloid leukemia transformation.
Pathways to Approval of Pediatric Cardiac Devices in the United States: Challenges and Solutions
Beekman, Robert H., Duncan, Brian W., Hagler, Donald J. , Jones, Thomas K. , Kugler, John D., Moore, John W. , Jenkins, Kathy J.

Mayo Clinic

Pediatrics | June 29, 2009 | Volume: 124 | Issue: 1 | Pages: e155-e162

10.1542/peds.2008-3726 | PMID 19564262 Get It

Patients treated by pediatric interventional cardiologists and cardiac surgeons often have unmet medical device needs that pose a challenge to the current regulatory evaluation and approval process in the United States. In this report we review current US Food and Drug Administration regulatory processes, review some unique aspects of pediatric cardiology and cardiac surgery that pose challenges to these processes, and discuss possible alternate pathways to cardiac device evaluation and approval for children. Children deserve to benefit from new and refined cardiac devices and technology designed explicitly for their conditions.
O2‐06‐04: Intraneuronal Aβ accumulation in Alzheimer's disease
Poduslo, Joseph F., Gilles, Emily J., Ramakrishnan, Muthu, Wengenack, Thomas M., Curran, Geoffry L., Kandimalla, Karunya K.

Mayo Clinic

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_4 | Pages: No page available

10.1016/j.jalz.2009.05.364 Get It

P2‐107: Intracranial Atherosclerosis as a contributing factor to Alzheimer's disease Dementia
Kokjohn, Tyler A., Maarouf, Chera L., Sabbagh, Marwan N. , Bëlohlávek, Marek , Garami, Zsolt , Beach, Thomas G., Roher, Alex E.

Mayo Clinic

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_10 | Pages: No page available

10.1016/j.jalz.2009.04.418 Get It

P2‐106: Echocardiography vortex formation time reveal cardiac diastolic transmitral flow dysfunction in Alzheimer's disease patients
Roher, Alex E., Bëlohlávek, Marek , Maarouf, Chera L., Kokjohn, Tyler A., Garami, Zsolt , Beach, Thomas G., Sabbagh, Marwan Noel

Mayo Clinic

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_10 | Pages: No page available

10.1016/j.jalz.2009.04.417 Get It